Testing effectiveness (Phase 2)WithdrawnNCT03098355
What this trial is testing
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Who this might be right for
B-Cell LeukemiaB-Cell Lymphoma
Zhujiang Hospital